Advanced Medical Solutions (AMS) saw its shares leap after H.B. Fuller, the Minnesota-headquartered industrial adhesives maker, put forward a recommended all-cash offer of 285 pence per AMS share. The proposal implies an enterprise value in the vicinity of A3715 million and prompted a 16.1% rise in AMS stock to 278.61p.
The AMS board said it unanimously recommends shareholders accept H.B. Fuller's offer. Chairman Grahame Cook was quoted by the board, noting that "The AMS directors are pleased to unanimously recommend the acquisition, which delivers attractive and certain value in cash to AMS shareholders."
The 285p offer equates to a premium of about 34.8% compared with AMS's 212p closing price on May 20, 2026, the last trading day before the formal offer period began. The market reaction narrowed the gap between the share price and the offer level as investors assessed the likelihood of completion.
H.B. Fuller provided quantified expectations for the combination, saying it anticipates roughly $55 million in combined run-rate revenue and cost synergies by 2031. The acquirer also projects the deal will expand its total addressable market by $15 billion to reach $95 billion, and to contribute approximately $300 million in annual revenues.
Analysts have noted that takeover chatter around AMS is not new. Stifel a0analyst Christian Glennie observed that this is the fifth instance of confirmed or possible takeover interest in AMS in roughly 20 months. That pattern includes the collapse of a TA Associates proposal in May 2026 and prior interest from Montagu Private Equity.
Market-wide conditions provided little assistance to the share move. The broader UK and U.S. indexes were mixed, so the sharp upswing in AMS stock appears to have been driven directly by the terms of H.B. Fuller's bid and the board's recommendation rather than by a market rally.
Investors responded to the combination of a firm cash proposal, a board-backed recommendation and the company a0 s history as a repeated acquisition target. With H.B. Fuller indicating a timetable that targets deal close by year-end 2026, the stock price has moved substantially closer to the offer level, reflecting market confidence that the transaction will likely progress to completion.
Context and implications
The transaction is structured as an all-cash acquisition at a notable premium to recent trading levels, and includes projected synergies and revenue uplift that H.B. Fuller expects to achieve post-integration. The board's unanimous recommendation removes a key source of uncertainty for shareholders evaluating the offer.
What remains to be resolved
While the market has largely priced in the bid, completion still depends on the deal process running its course before the targeted year-end 2026 close. Until the transaction is formally completed, the share price may continue to trade in close relation to the offer level.